Cargando…

Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X

Background: BRCA1 and BRCA2 are high-penetrance inherited genes; different founder mutations have been reported in various areas and races. By using trial registration data from the Japanese hereditary breast and ovarian cancer syndrome (HBOC) consortium, we aimed to explore the clinicopathological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Reiko, Watanabe, Chie, Yokoyama, Shiro, Inuzuka, Mayuko, Yotsumoto, Junko, Arai, Masami, Nakamura, Seigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524931/ https://www.ncbi.nlm.nih.gov/pubmed/31143373 http://dx.doi.org/10.18632/oncotarget.26852

Ejemplares similares

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2017)

Correction: Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2018)

BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ
por: Liu, Yan, et al.
Publicado: (2019)

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome
por: Kaneyasu, Tomoko, et al.
Publicado: (2020)

High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan
por: Yamauchi, Hideko, et al.
Publicado: (2018)

The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan
por: Murakami, Wakana, et al.
Publicado: (2019)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Brca1 (L63X) (/+) rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation‐induced mammary cancer
por: Nakamura, Yuzuki, et al.
Publicado: (2022)

Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations
por: Sato, Katsutoshi, et al.
Publicado: (2017)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Nonsense Mutation at Codon 63 of the BRCA1 Gene in Japanese Breast Cancer Patients
por: Kijima, George, et al.
Publicado: (1998)

The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study
por: Mitamura, Takashi, et al.
Publicado: (2021)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1
por: Caleca, Laura, et al.
Publicado: (2014)

Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
por: Sekine, Masayuki, et al.
Publicado: (2022)

Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan
por: Tozaki, Mitsuhiro, et al.
Publicado: (2017)

Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers
por: Shimada, Satoko, et al.
Publicado: (2019)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
por: Alvarez, Carolina, et al.
Publicado: (2017)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003)

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
por: Ławniczak, Małgorzata, et al.
Publicado: (2016)

Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity
por: Bu, Rong, et al.
Publicado: (2023)

Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G
por: Claes, Kathleen, et al.
Publicado: (1999)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study
por: Kowalik, Artur, et al.
Publicado: (2018)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
por: Janavičius, Ramūnas
Publicado: (2010)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Gender-specific factors associated with the Japanese version of the trail making test among Japanese workers
por: Inomoto, Atsushi, et al.
Publicado: (2023)

BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (c.798_799delTT) in North African
por: Laraqui, Abdelilah, et al.
Publicado: (2015)

BRCA1 and BRCA2 screening of nine Chilean founder mutations through allelic-discrimination and real-time PCR in breast/ovarian cancer patients
por: Alvarez, Carolina, et al.
Publicado: (2022)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients
por: Fragoso-Ontiveros, Veronica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qhhdklh1t1a8hfd2mk0k0ve1eh